Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q3 EPS of ($0.57), $0.08 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $2.25 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.